Project Grant R01CA294651
Award Date
4/3/25
Completion Date
3/31/30
Dollars Obligated
$642K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,658 to New York University School of Medicine to conduct research on understanding the regulation of pyrimidine metabolism and its impact on cancer cell function and anti-tumor immunity. The research aims to:
Determine how pyrimidine overflow and disruption of the p53-dependent ribosome biogenesis checkpoint differentially affect cancer cells versus anti-cancer immune...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $656,237 to Duke University to develop nucleic acid binding polymers that can scavenge extracellular nucleic acid-containing damage-associated molecular patterns (DAMPs) in the setting of pancreatic cancer therapy. The goal is to safely and effectively mitigate the activation of cancer cell migration and metastasis that can occur due to the release of such DAMPs during...
This $1,264,474 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the University of Pittsburgh's research on "Molecular Insights into Immune Suppression in Kidney Cancer and Novel Therapeutic Opportunities". The grant, effective September 1, 2024 through August 31, 2028, will fund the university's investigations into improving understanding of immune system mechanisms involved in kidney cancer and...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $176,712 to the University of Pittsburgh to support research on co-stimulation of T cell responses to nascent, emerging tumors. The key objectives are to develop a new mouse model to investigate the role of the CD91 receptor in providing co-stimulation and cytokines that are essential for priming T cell responses against emerging cancer cells. This...
This $649,679 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will fund research conducted by The Institute For Cancer Research to investigate a novel strategy for enhancing cancer immunotherapy responsiveness. The project aims to determine if targeting the RNA/DNA helicase DHX9 can induce "viral mimicry" in small cell lung cancer cells, triggering an antiviral immune response and improving the efficacy of immune checkpoint blockade...
This Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, provides $208,415.00 in funding to Duke University to conduct research on the mechanisms of macrophage-mediated immune evasion in residual tumors. The research aims to investigate how residual cancer cells evade the immune system, specifically by upregulating "don't eat me" markers like CD47, following treatment with oncogene-targeted therapies. The project...
This $346,319 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research at the University of Pittsburgh on intragenic rearrangement burden as a genomic predictor of immunotherapy benefit in triple-negative breast cancer. The objective is to conduct innovative scientific studies that could improve health outcomes for military service members, veterans, and the broader public. The award spans a 3-year...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $514,582 to the University of North Carolina at Chapel Hill to conduct research on targeting APOBEC3-induced squamous differentiation in bladder cancer. The research aims to better understand the role of APOBEC3 enzymes in bladder cancer initiation and progression, with a focus on how APOBEC3 promotes squamous differentiation and potential links to treatment resistance....
This $1,541,823 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to develop fast, targeted, and individualized cancer treatments for metastatic cancer patients with pleural disease. The 4-year award, which began on November 1, 2024, will be conducted by the University of Pittsburgh, a major recipient of federal research grants across biomedical disciplines. The university will leverage its extensive...
This $846,182 Project Grant award to the University of Pittsburgh was made by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project titled "INTRAGENIC REARRANGEMENT BURDEN AS A GENOMIC PREDICTOR OF IMMUNOTHERAPY BENEFIT IN TRIPLE-NEGATIVE BREAST CANCER" with a performance period from Aug 1, 2024 to Jul 31, 2027. As a major research university, the University of Pittsburgh will leverage its...